CN101129970A - Traditional Chinese medicine for treating metaphase and advanced liver cancer - Google Patents

Traditional Chinese medicine for treating metaphase and advanced liver cancer Download PDF

Info

Publication number
CN101129970A
CN101129970A CNA2007101317292A CN200710131729A CN101129970A CN 101129970 A CN101129970 A CN 101129970A CN A2007101317292 A CNA2007101317292 A CN A2007101317292A CN 200710131729 A CN200710131729 A CN 200710131729A CN 101129970 A CN101129970 A CN 101129970A
Authority
CN
China
Prior art keywords
gram
radix
grams
rhizoma
parched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007101317292A
Other languages
Chinese (zh)
Inventor
尹克山
Original Assignee
尹克山
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 尹克山 filed Critical 尹克山
Priority to CNA2007101317292A priority Critical patent/CN101129970A/en
Publication of CN101129970A publication Critical patent/CN101129970A/en
Pending legal-status Critical Current

Links

Abstract

The invention provides a Chinese medicinal capsule for treating late phase liver cancer, wherein the recipe includes Bupleurum root, zedoary, pinellia tuber, dried orange peel, amomum fruit each 12g, Hypericum japonicum Thunb. , raw astragalus root, oldenlandia, dandehon herb each 30g, pilose asiabell root, poria cocos wolf each 20g, white atractylodes rhizome, fructus akebiae each 15g, centipede 2 pieces, haw, medicated leaven, malt each 10g, licorice root 6g, artemisia capillaris thumb, red phaseolus bean each 30g, rhubarb horsetails 6g, poria peel, polyporus umbellatus, oriental water plantain rhizome, waxgourd peel each 30g, notoginseng powder 3g, bletilla tuber 12g, garden burnet root 15g. The Chinese medicament has simplified recipe, easy preparing process and low price.

Description

The Chinese medicine of treatment mid and late liver cancer
Technical field
The present invention relates to a kind of Chinese medicine for the treatment of hepatocarcinoma, particularly a kind of Chinese medicine for the treatment of mid and late liver cancer.
Background technology
Hepatocarcinoma means hepatocyte or the cytogenetic canceration of stones in intrahepatic bile duct.With liver carrying out property enlargement and pain, jaundice is generated heat clinically, and ascites is hemorrhage, and the alpha-fetoglobulin positive etc. is main performance.
At present, when people's paralysis has the mid and late liver cancer disease, in the flourishing city of medical condition, people are hospital treatments, generally all be to use Western medicine or have an injection and treat, and in the small towns, more particularly away from the small towns, outlying village is when people's paralysis has the disease of mid and late liver cancer, because family income is low, living in penury, the locality lacks medical condition, needs expensive travelling expenses to go to the flourishing city of medical condition to go to seek medical advice if want to cure the disease, the medical expense of hospital and medical expenses costliness in addition, people's treatment of often not going sick, the recovery from illness of giving free rein to, therefore some patient has incured loss through delay treatment opportunity.
Summary of the invention
The objective of the invention is to provide a kind of: the Chinese medicine of the treatment mid and late liver cancer that expense is cheap.
The technical scheme that solves its technical problem employing is: the main formula agent: Radix Bupleuri, Rhizoma Curcumae, Rhizoma Pinelliae, Pericarpium Citri Reticulatae, each 12 gram of Fructus Amomi, Herba Hyperici Japonici, Radix Astragali, Herba Hedyotidis Diffusae, each 30 gram of Herba Taraxaci, Radix Codonopsis, each 20 gram of Poria, Rhizoma Atractylodis Macrocephalae (parched), each 15 gram of Fructus Akebiae, 2 of Scolopendras, Fructus Crataegi (parched to brown), Massa Medicata Fermentata (parched to brown), each 10 gram of Fructus Hordei Germinatus (parched to brown), Radix Glycyrrhizae 6 grams; Auxiliary prescription: companion jaundice person adds Herba Artemisiae Scopariae, each 30 gram of Semen Phaseoli, Radix Et Rhizoma Rhei 6 grams; Companion's abdominal distention, edema of pair of lower extremities, oliguria person add Cortex Sclerotii Poriae, Polyporus, Rhizoma Alismatis, each 30 gram of Exocarpium Benincasae; Companion's hematemesis, melena person add Radix Notoginseng powder 3 grams, Pseudobulbus Bletillae (Rhizoma Bletillae) 12 grams, charred Radix Sanguisorbae 15 grams.
Beneficial effect: owing to adopted such scheme, the material that makes up a prescription in the prescription all uses natural Chinese herbal medicines, adds that then traditional concocting method is made, material is easily got, prescription and preparation method are simple, and preparation medicine expense is cheap, has reached purpose of the present invention.This Chinese herbal medicine compatibility is simple, employed medicine uses natural herbal fully in the pharmaceutical formulation, it is convenient to get, use, manufacture method is simple, it is good to take therapeutic effect, drug price is cheap, can adapt to the people that live in away from small towns, outlying village especially and use, and has people's medical expense of mid and late liver cancer disease cheap to paralysis.
This Chinese herbal medicine is a prescription handed down from one's ancestors, cures mainly mid and late liver cancer.With 300 milliliters of decoctings, Radix Notoginseng powder is taken after mixing it with water, and divides 2 clothes sooner or later, 1 dose of every day, takes continuously 90 days.Use this prescription to treat mid and late liver cancer patient 256 examples, wherein use cure 87 examples a course of treatment, account for 34%; Use cure 93 examples two courses of treatment, account for 36%; Use cure 51 examples three above courses of treatment, account for 20%; Disease controlling 24 examples account for 9%; Readily good therapeutic effect 2 examples account for 1%, and obvious to mid and late liver cancer disease cured rate effect, the patient of readily good therapeutic effect only accounts for 1%, and paralysis person takes in the therapeutic process of this prescription, does not produce untoward reaction.
The specific embodiment
Embodiment 1: the main formula agent: Radix Bupleuri, Rhizoma Curcumae, Rhizoma Pinelliae, Pericarpium Citri Reticulatae, each 12 gram of Fructus Amomi, Herba Hyperici Japonici, Radix Astragali, Herba Hedyotidis Diffusae, each 30 gram of Herba Taraxaci, Radix Codonopsis, each 20 gram of Poria, Rhizoma Atractylodis Macrocephalae (parched), each 15 gram of Fructus Akebiae, 2 of Scolopendras, Fructus Crataegi (parched to brown), Massa Medicata Fermentata (parched to brown), each 10 gram of Fructus Hordei Germinatus (parched to brown), Radix Glycyrrhizae 6 grams; Auxiliary prescription: companion jaundice person adds Herba Artemisiae Scopariae, each 30 gram of Semen Phaseoli, Radix Et Rhizoma Rhei 6 grams; Companion's abdominal distention, edema of pair of lower extremities, oliguria person add Cortex Sclerotii Poriae, Polyporus, Rhizoma Alismatis, each 30 gram of Exocarpium Benincasae; Companion's hematemesis, melena person add Radix Notoginseng powder 3 grams, Pseudobulbus Bletillae (Rhizoma Bletillae) 12 grams, charred Radix Sanguisorbae 15 grams.

Claims (1)

1. Chinese medicine for the treatment of mid and late liver cancer, it is characterized in that: the main formula agent: Radix Bupleuri, Rhizoma Curcumae, Rhizoma Pinelliae, Pericarpium Citri Reticulatae, each 12 gram of Fructus Amomi, Herba Hyperici Japonici, Radix Astragali, Herba Hedyotidis Diffusae, each 30 gram of Herba Taraxaci, Radix Codonopsis, each 20 gram of Poria, Rhizoma Atractylodis Macrocephalae (parched), each 15 gram of Fructus Akebiae, 2 of Scolopendras, Fructus Crataegi (parched to brown), Massa Medicata Fermentata (parched to brown), each 10 gram of Fructus Hordei Germinatus (parched to brown), Radix Glycyrrhizae 6 grams; Auxiliary prescription: companion jaundice person adds Herba Artemisiae Scopariae, each 30 gram of Semen Phaseoli, Radix Et Rhizoma Rhei 6 grams; Companion's abdominal distention, edema of pair of lower extremities, oliguria person add Cortex Sclerotii Poriae, Polyporus, Rhizoma Alismatis, each 30 gram of Exocarpium Benincasae; Companion's hematemesis, melena person add Radix Notoginseng powder 3 grams, Pseudobulbus Bletillae (Rhizoma Bletillae) 12 grams, charred Radix Sanguisorbae 15 grams.
CNA2007101317292A 2007-08-29 2007-08-29 Traditional Chinese medicine for treating metaphase and advanced liver cancer Pending CN101129970A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNA2007101317292A CN101129970A (en) 2007-08-29 2007-08-29 Traditional Chinese medicine for treating metaphase and advanced liver cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA2007101317292A CN101129970A (en) 2007-08-29 2007-08-29 Traditional Chinese medicine for treating metaphase and advanced liver cancer

Publications (1)

Publication Number Publication Date
CN101129970A true CN101129970A (en) 2008-02-27

Family

ID=39127482

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007101317292A Pending CN101129970A (en) 2007-08-29 2007-08-29 Traditional Chinese medicine for treating metaphase and advanced liver cancer

Country Status (1)

Country Link
CN (1) CN101129970A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101700386B (en) * 2009-11-12 2011-05-11 范先明 Traditional Chinese medicine composition resistant to liver cancer and medicine coat thereof
CN102058744A (en) * 2010-11-25 2011-05-18 代龙 Chinese medicinal composition for treating malignant tumor and preparation method thereof
CN101301337B (en) * 2008-06-03 2011-09-21 陈德顺 Chinese medicine preparation for treating hepatic cirrhosis induced haematemesis
CN103751547A (en) * 2014-01-21 2014-04-30 四川绿禾药业有限公司 Traditional Chinese medicinal composition for reducing blood lipid and preparation method thereof
CN105213613A (en) * 2015-10-30 2016-01-06 葛忠 A kind of Chinese medicine composition of Hepatoma therapy
CN113952435B (en) * 2021-11-05 2022-06-17 甘肃兰药药业有限公司 Traditional Chinese medicine composition for adjuvant treatment of liver cancer and preparation method thereof

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101301337B (en) * 2008-06-03 2011-09-21 陈德顺 Chinese medicine preparation for treating hepatic cirrhosis induced haematemesis
CN101700386B (en) * 2009-11-12 2011-05-11 范先明 Traditional Chinese medicine composition resistant to liver cancer and medicine coat thereof
CN102058744A (en) * 2010-11-25 2011-05-18 代龙 Chinese medicinal composition for treating malignant tumor and preparation method thereof
CN103751547A (en) * 2014-01-21 2014-04-30 四川绿禾药业有限公司 Traditional Chinese medicinal composition for reducing blood lipid and preparation method thereof
CN105213613A (en) * 2015-10-30 2016-01-06 葛忠 A kind of Chinese medicine composition of Hepatoma therapy
CN113952435B (en) * 2021-11-05 2022-06-17 甘肃兰药药业有限公司 Traditional Chinese medicine composition for adjuvant treatment of liver cancer and preparation method thereof

Similar Documents

Publication Publication Date Title
CN101129552A (en) Traditional Chinese medicine for treating chronic functional constipation
CN101152535A (en) Traditional Chinese medicine for treating subacute thyroiditis
CN101129771A (en) Traditional Chinese medicine for treating bradykinesia type constipation
CN101129593A (en) Traditional Chinese medicine for treating senility habitual constipation
CN101152433A (en) Traditional Chinese medicine for treating chemotherapy leukocytopenia after mammary cancer operation
CN101152331A (en) Traditional Chinese medicine for treating Qi asthenia type hemorrhoid hemorrhage
CN101129970A (en) Traditional Chinese medicine for treating metaphase and advanced liver cancer
CN101129945A (en) Traditional Chinese medicine for treating diffuse liver cancer
CN101129594A (en) Traditional Chinese medicine for treating rheumatic arthritis
CN101129617A (en) Traditional Chinese medicine for treating cirrhosis
CN101130000A (en) Traditional Chinese medicine for treating postoperative constipation
CN101129966A (en) Traditional Chinese medicine for treating thyroid hyperfunction companioned with diarrhea
CN101152518A (en) Traditional Chinese medicine for treating chemotherapy adverse effect after mammary cancer operation
CN101518640A (en) Chinese traditional medicine prescription for treating tumor
CN101152282A (en) Traditional Chinese medicine for treating tumefaction of membrum superius after mammary cancer operation
CN101130051A (en) Traditional Chinese medicine for treating stomach cancer
CN101167893A (en) Traditional Chinese medicine for treating viral hepatitis
CN101152519A (en) Traditional Chinese medicine for treating gestational hypertension complex
CN101164611A (en) Traditional Chinese medicine for treating invasion of lung by cold type pertussis
CN101167932A (en) Traditional Chinese medicine for treating chronic hepatitis B
CN1332707C (en) Formula of Chinese herbal medicine decoction distinguished from males and females and combined with Western medicine for curing hepatitis B
CN101152494A (en) Traditional Chinese medicine for treating acute appendicitis
CN101129967A (en) Traditional Chinese medicine for treating diabetes diarrhea
CN101152540A (en) Chinese traditional medicine for treating chronic hepatitis
CN101129893A (en) Traditional Chinese medicine for treating cervical vertebra disease combined with diarrhea

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080227